GLP-1

News

EMA finds no evidence GLP-1 agonists cause thyroid cancer

The EMA’s safety committee has said that, after a review of available data, it has found no evidence that GLP-1 agonist drugs such as Novo Nordisk’s Ozempic and Eli Lilly’

Patients

Why medical weight loss is more complicated than GLP-1s

A few weeks ago on the pharmaphorum podcast, we discussed the new GLP-1 weight loss drugs and their shake-up effect on the medical weight loss industry.

News

Novo Nordisk’s semaglutide aces another outcomes trial

Novo Nordisk has halted a phase 3 trial of its Ozempic formulation of GLP-1 agonist semaglutide in patients with type 2 diabetes and chronic kidney disease (CKD) early aft

News

EMA probes suicide risk with Novo Nordisk obesity drugs

The European Medicines Agency (EMA) has started a review of two Novo Nordisk drugs used to treat obesity and those overweight, following reports of suicidal thoughts or se

News

CHMP backs obesity drug Wegovy for teens

Novo Nordisk’s sought-after obesity drug Wegovy could be approved in the EU shortly for use in adolescents as well as adults.

News

close up of a prescription bottle with white tables falling out on top of a group of hundred dollar bills

Sosei nets $10m Pfizer milestone as diabetes/obesity drug st...

Sosei Heptares' longstanding alliance with Pfizer has advanced a first candidate into phase 2 testing: an oral GLP-1 agonist for diabetes and obesity that will try to take on established ri

EMA finds no evidence GLP-1 agonists cause thyroid cancer

Why medical weight loss is more complicated than GLP-1s

Novo Nordisk’s semaglutide aces another outcomes trial

EMA probes suicide risk with Novo Nordisk obesity drugs

CHMP backs obesity drug Wegovy for teens

Sosei nets $10m Pfizer milestone as diabetes/obesity drug st...

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

GLP-1

Editor's Picks